These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 17699445)

  • 21. Advertising, sponsorship, and conflict of interest.
    Lewis PR
    J Fam Pract; 2007 May; 56(5):344. PubMed ID: 17475163
    [No Abstract]   [Full Text] [Related]  

  • 22. Erythropoiesis-stimulating agents in patients with cancer: update on safety issues.
    Pirker R
    Expert Opin Drug Saf; 2009 Sep; 8(5):515-22. PubMed ID: 19637988
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The influence of the pharmaceutical industry on treatment guidelines].
    Kramers C; Wuis E; Schouwenberg B
    Ned Tijdschr Geneeskd; 2008 Jan; 152(2):114; author reply 114. PubMed ID: 18265803
    [No Abstract]   [Full Text] [Related]  

  • 24. [Anemia in kidney diseases].
    Popławski A
    Przegl Lek; 1995; 52(3):78-9. PubMed ID: 7644676
    [No Abstract]   [Full Text] [Related]  

  • 25. September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents.
    Aapro MS; Link H
    Oncologist; 2008; 13 Suppl 3():33-6. PubMed ID: 18458123
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anemia: the point of convergence or divergence for kidney disease and heart failure?
    Kazory A; Ross EA
    J Am Coll Cardiol; 2009 Feb; 53(8):639-47. PubMed ID: 19232895
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Renal anemia: comparing current Eastern and Western European management practice (ORAMA).
    Wiecek A; Covic A; Locatelli F; Macdougall IC;
    Ren Fail; 2008; 30(3):267-76. PubMed ID: 18350446
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Guidelines have done more harm than good.
    Amerling R; Winchester JF; Ronco C
    Blood Purif; 2008; 26(1):73-6. PubMed ID: 18182801
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Conflict of interest and therapy recommendations].
    Laake JH
    Tidsskr Nor Laegeforen; 2004 Oct; 124(20):2663-4; author reply 2664. PubMed ID: 15534654
    [No Abstract]   [Full Text] [Related]  

  • 30. Anabolic treatment for anemia.
    AIDS Patient Care STDS; 1998 Jun; 12(6):497-8. PubMed ID: 11362006
    [No Abstract]   [Full Text] [Related]  

  • 31. Effect of computer-assisted European Best Practice Guideline implementation on adherence and target attainment: ORAMA results.
    Locatelli F; Covic A; Macdougall IC; Scherhag A; Wiecek A;
    J Nephrol; 2009; 22(5):662-74. PubMed ID: 19810000
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treating anemia at different stages of renal disease.
    Locatelli F; Del Vecchio L; Pozzoni P
    J Nephrol; 2007; 20 Suppl 12():S33-8. PubMed ID: 18050140
    [TBL] [Abstract][Full Text] [Related]  

  • 33. KDOQI US commentary on the KDIGO clinical practice guideline for the prevention, diagnosis, evaluation, and treatment of hepatitis C in CKD.
    Gordon CE; Balk EM; Becker BN; Crooks PA; Jaber BL; Johnson CA; Michael MA; Pereira BJ; Uhlig K; Levin A
    Am J Kidney Dis; 2008 Nov; 52(5):811-25. PubMed ID: 18971009
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Conflict of interest statement for industry-sponsored article.
    Chokroverty S
    Sleep Med; 2009 Sep; 10(8):817. PubMed ID: 19699461
    [No Abstract]   [Full Text] [Related]  

  • 35. Outpatient management of chronic kidney disease: proteinuria, anemia and bone disease as therapeutic targets.
    Lam A; Shah S; Paparello J
    Am J Ther; 2008; 15(3):278-86. PubMed ID: 18496265
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transition of patients from chronic kidney disease to end-stage renal disease: better practices for better outcomes.
    Amedia CA; Perazella MA
    Dis Manag; 2006 Dec; 9(6):311-5. PubMed ID: 17115878
    [No Abstract]   [Full Text] [Related]  

  • 37. [Anemia in chronic renal disease: ferrokinetic aspect of renal anemia].
    Takasugi M; Yoshimatsu H; Takeuchi K; Nakao M; Minoda H
    Saishin Igaku; 1970 Feb; 5(2):330-6. PubMed ID: 4908909
    [No Abstract]   [Full Text] [Related]  

  • 38. Optimizing anemia management in hospitalized patients with end-stage renal disease.
    Heung M; Mueller BA; Segal JH
    Ann Pharmacother; 2009 Feb; 43(2):276-82. PubMed ID: 19141655
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treating anemia with erythropoiesis-stimulating agents: effects on quality of life.
    Moossavi S; Freedman BI
    Arch Intern Med; 2009 Jun; 169(12):1100-1. PubMed ID: 19546408
    [No Abstract]   [Full Text] [Related]  

  • 40. [Statins and the industry].
    Kjellevand TO
    Tidsskr Nor Laegeforen; 2009 Nov; 129(21):2264. PubMed ID: 19898587
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.